SBIR PHASE II, TOPIC 429: A NEW PARADIGM FOR AUTOLOGOUS AND ALLOGENEIC CELL THERAPY MANUFACTURING

点击翻译按钮获取中文摘要

Autologous cell-based therapies offer great promise for cancer treatment however they are complex, slow, labor intensive and expensive. Medical center laboratories usually have a limited capacity and they can rarely treat more than 10 patients per month. Advanced manufacturing approaches that can process multiple cell therapies for several patients in parallel are desperately needed to improve the availability of these emerging cell-based therapies. Fully-automated systems would improve the throughput of this technology and are expected to decrease both time and cost of these emerging technologies and ultimately make this treatment available to more patients. Proteios Technology will provide an at-scale prototype to isolate, activate, genetically modify, expand, and formulate cell-based therapies in a cGMP cell manufacturing setting. This project will provide the proof of concept for an at-scale prototype that Proteios will scale for manufacturing and launch commercially. When commercialized, Proteios’ cGMP instrument will reduce both the cost and the time of cell-based therapy manufacturing and will provide a point-of-care (POC) device that can operate near the patient and eliminate the need to transfer patient blood samples and resulting cell therapies to/from medical center laboratories.